Wednesday, September 9, 2026
spot_img

Mandatory disclosure of holding and notice of trade in IDEX Biometrics – 1 August 2025

Reference is made to IDEX Biometrics ASA’s disclosure on 21 July 2025 of a private placement of 9,090,909 shares at NOK 3.30 per share. IDEX discloses the following information on behalf of a major shareholder and primary insider.

Tranche 1 of the private placement amounted to 4,731,594 shares. All shares was lent, not sold, by CEO and CFO Anders Storbråten.

The shares – 4,731,594 – is now returned to Anders Storbråten. Storbråten and close relations hold 11,235,070 shares or 21,57 % shares of the total outstanding shares and votes in IDEX Biometrics after completion of Tranche 1.

IDEX Biometrics’ reports and presentations are available on our website: www.idexbiometrics.com/investors

For further information, please contact: Anders Storbråten, CEO and CFO, Tel: +47 416 38 582

E-mail: [email protected]

About IDEX Biometrics:

IDEX Biometrics ASA (IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market.
For more information, visit www.idexbiometrics.com

About this notice:

This notice was issued by Kjell-Arne Besseberg, COO, on 1 August 2025 at 18:00 CEST on behalf of IDEX Biometrics ASA. The information about the lending shall be disclosed according to article 19 no. 3 of the EU Market Abuse Regulation (EU 596/2014). The information about shareholding shall be disclosed according to section 4-2 of the Norwegian Securities Trading Act (STA). The information is published in accordance with section 5-12 of the Norwegian Securities Trading Act.

Powered by SlickText.com

Hot this week

Form 8.3 – Picton Property Income Limited

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A...

Form 8.3 – NextEnergy Solar Fund Limited

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A...

Form 8.3 – LondonMetric Property Plc & Schroder Real Estate Investment Trust Limited

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A...

Decisions of the Richemont 2026 Annual General Meeting

9 SEPTEMBER 2026 DECISIONS OF THE RICHEMONT 2026...

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist...

Topics

Form 8.3 – Picton Property Income Limited

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A...

Form 8.3 – NextEnergy Solar Fund Limited

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A...

Form 8.3 – LondonMetric Property Plc & Schroder Real Estate Investment Trust Limited

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A...

Decisions of the Richemont 2026 Annual General Meeting

9 SEPTEMBER 2026 DECISIONS OF THE RICHEMONT 2026...

Azimut Accelerates District-Scale Gold Exploration at Wabamisk

30 km by 2 km prospective corridor encompasses Rosa...
spot_img

Related Articles

Popular Categories

spot_img